3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
30
Terminated
11
Withdrawn
3
Active not recruiting
2
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
pembrolizumab
551
Specimen Handling
465
Carboplatin
441
Magnetic Resonance Spectroscopy
430
Cyclophosphamide
412
Cisplatin
397
Radiotherapy
313
Gemcitabine
309
Bevacizumab
307
Paclitaxel
294
Biopsy
261
Drug Therapy
249
Capecitabine
242
Oxaliplatin
239
fludarabine
237
Nivolumab
224
venetoclax
219
Injections
213
Docetaxel
205
Fluorouracil
203
Dexamethasone
187
Radiosurgery
172
Rituximab
158
Pemetrexed
153
Standard of Care
146
durvalumab
143
Leucovorin
139
atezolizumab
138
toripalimab
134
tislelizumab
134
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Interventional
×
MK 2206
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled